Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Folate-Targeted Polyacrylamide/Punicic Acid Nanomicelles for Flutamide Delivery in Prostate Cancer: Characterization, In Vitro Biological Evaluation, and its DFT Study

Author(s): Razieh Mirsafaei, Jaleh Varshosaz* and Seyed N. Mirsattari

Volume 14, Issue 4, 2020

Page: [360 - 374] Pages: 15

DOI: 10.2174/1872210514666200513092614

Price: $65

Abstract

Background: Targeted nanocarriers can be used for reducing the unwanted side effects of drugs in non-target organs. Punicic acid, the polyunsaturated fatty acid of pomegranate seed oil, has been shown to possess anti-cancer effects on prostate cancer and the study also covers recent patents related to prostate cancer. The objective of the current study was to synthesize a co-polymeric micelle for delivery of Flutamide (FL) in prostate cancer using Polyacrylamide (PAM) and Punicic Acid (PA).

Methods: The co-polymer of PAM and PA was synthesized and conjugated to folic acid. The successful conjugation was studied computationally by the density functional theory method and was confirmed by the FT- IR and 1HNMR. The folate-PAMPA micelles produced by the film casting method were characterized physically. FL was loaded in the nanomicelles and its release test was done at different pH. The Critical Micelle Concentration (CMC) was measured by pyrene as a fluorescent probe. Their cellular uptake and cytotoxicity were evaluated on PC3 prostate cancer cells. The molecular geometry and vibrational frequencies of two different possibilities for conjugation were calculated using the B3LYP/6-31G basis set.

Results: The CMC of the micelles and their particle size were 79.05 μg/ml and 88 nm, respectively. The resulting nanocarriers of FL showed significantly more cytotoxic effects than the free drug at a concentration of 25 μM. The calculated results showed that the optimized geometries could well reproduce the structural parameters, and the theoretical vibrational frequencies were in good agreement with the experimental values.

Conclusion: Folate-PAMPA nanomicelles may be promising for the enhancement of FL cytotoxicity and seem to potentiate the effect of chemotherapeutic agents used in prostate cancer treatment.

Keywords: Cancer, drug delivery, flutamide, folate, poly (acrylamide)/punicic acid, nanomicelles.

« Previous Next »
Graphical Abstract

[1]
Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324(4): 236-45.
[http://dx.doi.org/10.1056/NEJM199101243240406] [PMID: 1985245]
[2]
Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50(1): 7-33.
[http://dx.doi.org/10.3322/canjclin.50.1.7] [PMID: 10735013]
[3]
Tachibana K, Sato H, Ohta M, et al. Imidazolidine derivatives. WO Patent 111012 2004.
[4]
Andrew HD, James MCT, Godfrey F. Imidazolidine derivatives. CA Patent 853218A, 1970..
[5]
Furr B, Cockshott I. Pharmaceutical combination of an antiandrogen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition. US Patent 20030158160A1, 2003..
[6]
Stupak E, Cho PW. Controlled release flutamide composition. EP Patent 0543541A1, 1993..
[7]
Gohy JF. Block Copolymer Micellesblock Copolymers II. Berlin, Heidelberg: Springer 2005; pp. 65-136.
[http://dx.doi.org/10.1007/12_048]
[8]
Chen Q, Yang Y, Lin X, et al. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance. Chem Commun (Camb) 2018; 54(42): 5369-72.
[http://dx.doi.org/10.1039/C8CC02791A] [PMID: 29744485]
[9]
Ju J, Peng X, Huang K, et al. High-performance porous PLLA-based scaffolds for bone tissue engineering: Preparation, characterization, and in vitro and in vivo evaluation. Polymer (Guildf) 2019; 180121707
[http://dx.doi.org/10.1016/j.polymer.2019.121707]
[10]
Gao S, Tang G, Hua D, et al. Stimuli-responsive bio-based polymeric systems and their applications. J Mater Chem B Mater Biol Med 2019; 7(5): 709-29.
[http://dx.doi.org/10.1039/C8TB02491J] [PMID: 32254845]
[11]
Kazunori K, Masayuki Y, Teruo O, Yasuhisa S. Block copolymer micelles as vehicles for drug delivery. J Control Release 1993; 24: 119-32.
[http://dx.doi.org/10.1016/0168-3659(93)90172-2]
[12]
Rösler A, Vandermeulen GW, Klok HA. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2012; 64: 270-9.
[http://dx.doi.org/10.1016/j.addr.2012.09.026] [PMID: 11733119]
[13]
Breitenkamp K. Polymeric micelles for drug delivery. US Patent 20060240092A1 2006.
[14]
Kwon G, Forrest M. Micelle composition of polymer and passenger drug. US Patent 20060251710A1 2006.
[15]
An FF, Zhang XH. Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. Theranostics 2017; 7(15): 3667-89.
[http://dx.doi.org/10.7150/thno.19365] [PMID: 29109768]
[16]
Beaudet N, Dupont C, Lemieux P, Simard E, Goyette P. An exopolysaccharides delivery system for active moleculesUnited States Patent 8088605, 2012.
[17]
Lam KS. Reversibly cross-linked micelle systems. EP Patent 2707419A2,. 2014.
[18]
Kwon GS, Bae Y, Alani AWG. Polymeric micelles for combination drug delivery. US Patent 20080248097A1. 2008.
[19]
Liang L. Micellar systems useful for delivery of lipophilic or hydrophobic compounds. EP Patent 1706098A2, 2005..
[20]
Han BY, Kun N, Seong LE. pH-sensitive polymeric micelles for drug delivery. US Patent 7951846 2011.
[21]
An FF, Ye J, Zhang JF, et al. Non-blinking, highly luminescent, pH- and heavy-metal-ion-stable organic nanodots for bio-imaging. J Mater Chem B Mater Biol Med 2013; 1(25): 3144-51.
[http://dx.doi.org/10.1039/c3tb20271b] [PMID: 32260914]
[22]
Deckner GE, Lombardo BS. Enhanced skin penetration system for improved topical delivery of drugs. US Patent 5874095A 1999.
[23]
Turner SR, Siano DB, Bock J. Micellar process for the production of acrylamide-alkyl acrylamide copolymers. US Patent 4528348A, 1985.
[24]
Bassaganya-Riera J. Method of using punicic acid to enhance immune response and prevent metabolic disorders. US Patent 8822543B2 2014.
[25]
Yvergnaux F, Couturier L. Punicic acid derivatives and use thereof in cosmetic and/or dermatological composition for weight loss purposes. WO Patent 2010094992A1. 2010.
[26]
Nagaraja P, Arun Kumar HR, Vasantha RA, Yathirajan HS. Novel reagents for the sensitive spectrophotometric determination of flutamide, an anticancer drug in pharmaceutical preparations. Int J Pharm 2002; 235(1-2): 113-20.
[http://dx.doi.org/10.1016/S0378-5173(01)00975-9] [PMID: 11879746]
[27]
Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects. J Urol 1995; 154(5): 1642-5.
[http://dx.doi.org/10.1016/S0022-5347(01)66734-X] [PMID: 7563310]
[28]
Dreher M, Lee V, Costelow J, Knight M. Pomegranate seed oil composition. US9205117B1. 2012.
[29]
MacFarlane JR, Tolley DA. Flutamide therapy for advanced prostatic cancer: A phase II study. Br J Urol 1985; 57(2): 172-4.
[http://dx.doi.org/10.1111/j.1464-410X.1985.tb06415.x] [PMID: 3986452]
[30]
Becke AD. Becke’s three parameter hybrid method using the LYP correlation functional. J Chem Phys 1993; 98: 5648.
[http://dx.doi.org/10.1063/1.464913]
[31]
Lee C, Yang W, Parr RG. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B Condens Matter 1988; 37(2): 785-9.
[http://dx.doi.org/10.1103/PhysRevB.37.785] [PMID: 9944570]
[32]
Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09, Revision A 02. Wallingford, CT: Gaussian Inc 2009. Available at:. https://gaussian.com/g09citation/
[33]
Dennington R, Keith T, Millam J. Gauss View, Version 412. Shawnee Mission, KS: Semichem Inc 2007.
[34]
Tian Y, Bromberg L, Lin SN, Hatton TA, Tam KC. Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers. J Control Release 2007; 121(3): 137-45.
[http://dx.doi.org/10.1016/j.jconrel.2007.05.010] [PMID: 17630011]
[35]
Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 2007; 28(3): 504-12.
[http://dx.doi.org/10.1016/j.biomaterials.2006.07.046] [PMID: 16996126]
[36]
Lartigue ML, Donnadieu B, Galliot C, Caminade AM, Majoral JP. Large dipole moments of phosphorus-containing dendrimers. Macromolecules 1997; 30: 7335-7.
[http://dx.doi.org/10.1021/ma970570s]
[37]
Lansky EP, Harrison G, Froom P, Jiang WG. Polyphenols are responsible for the proapoptotic properties of pomegranate juice on leukemia cell lines. Invest New Drugs 2005; 23: 121-2.
[http://dx.doi.org/10.1007/s10637-005-5856-7] [PMID: 15744587]
[38]
Gasmi J, Sanderson JT. Growth inhibitory, antiandrogenic, and pro-apoptotic effects of punicic acid in LNCaP human prostate cancer cells. J Agric Food Chem 2010; 58(23): 12149-56.
[http://dx.doi.org/10.1021/jf103306k] [PMID: 21067181]
[39]
Kim SY, Shin IG, Lee YM, Cho CS, Sung YK. Methoxy poly(ethylene glycol) and ε-caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviours. J Control Release 1998; 51(1): 13-22.
[http://dx.doi.org/10.1016/S0168-3659(97)00124-7] [PMID: 9685900]
[40]
Gaucher G, Marchessault RH, Leroux JC. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release 2010; 143(1): 2-12.
[http://dx.doi.org/10.1016/j.jconrel.2009.11.012] [PMID: 19925835]
[41]
Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004; 303(5665): 1818-22.
[http://dx.doi.org/10.1126/science.1095833] [PMID: 15031496]
[42]
Uma Devi T, Priya S, Selvanayagam S, Ravikumar K, Anitha K. Synthesis, structural elucidation and spectroscopic analysis of 3a,8b-dihydroxy-4-oxo-1H,2H,3H,3aH,4H,8bH-indeno[1,2-d]imidazolidin-2-iminium chloride. Spectrochim Acta A Mol Biomol Spectrosc 2012; 97: 1063-71.
[http://dx.doi.org/10.1016/j.saa.2012.07.118] [PMID: 22925983]
[43]
Sezgin Z, Yüksel N, Baykara T. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm 2006; 64(3): 261-8.
[http://dx.doi.org/10.1016/j.ejpb.2006.06.003] [PMID: 16884896]
[44]
Mcewan JF, Jones R, John G. Amplification of folate-mediated targeting to tumor cells using polymers. WO Patent 2000066091A1, 2000.
[45]
Chao Q, Grasso L, O’Shannessy DJ, et al. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alphaexpressing cancers. WO Patent 2012061759 A2 2012.
[46]
Low PS, Lu Y. Method of treatment using ligand-immunogen conjugates. US Patent 7033594B2 2006.
[47]
Leamon CP. Folate mimetics and folate-receptor binding conjugates thereof. US Patent 20050227985A9 2011.
[48]
Allen TM, Uster P, Martin FJ. Therapeutic liposome composition and method of preparation. US Patent 6316024B1, 2001..
[49]
Low PS, Poh S. Delivery of therapeutic agents to inflamed tissues using folate-targeted agents. WO Patent 2011150392A1, 2011..
[50]
Kennedy MD, Low P. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology. US Patent 8043603B2, 2011.
[51]
Chirwa N, Pillay V, Choonara YE, Kumar P, du Toit L. Pharmaceutical composition. US Patent 9220773 B2. 2015.

Rights & Permissions Print Cite
Article Metrics
15
© 2024 Bentham Science Publishers | Privacy Policy